Literature DB >> 20795437

HIV/AIDS surveillance in Egypt: current status and future challenges.

S Boutros1, J Skordis.   

Abstract

By international standards, HIV/AIDS prevalence is low in Egypt (< 0.1%). However, questions about the accuracy of this figure are coupled with fears of an imminent increase in prevalence, with evidence suggesting that, despite Egypt's conservative culture, high-risk behaviour is more widespread than commonly reported and the country's changing socioeconomic context is perpetuating this trend. Through an analysis of the current HIV/AIDS surveillance system in Egypt, this paper explores some of the unique challenges this country faces in dealing with the HIV/AIDS epidemic. It concludes that constraints, such as Egypt's cultural norms and laws, the population's lack of knowledge about HIV/AIDS and the bureaucratic health system, hinder the development and implementation of effective surveillance systems.

Entities:  

Mesh:

Year:  2010        PMID: 20795437

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  3 in total

1.  Epidemiological characterization and geographic distribution of human immunodeficiency virus/acquired immunodeficiency syndrome infection in North African countries.

Authors:  Mohamed A Daw; Mohamed O Ahmed
Journal:  World J Virol       Date:  2021-03-25

2.  Infection Control Knowledge, Attitudes, and Practices among Students of Public Dental Schools in Egypt.

Authors:  Christina El-Saaidi; Omid Dadras; Patou Masika Musumari; Masako Ono-Kihara; Masahiro Kihara
Journal:  Int J Environ Res Public Health       Date:  2021-06-09       Impact factor: 3.390

3.  Hepatitis C virus-specific cell-mediated immune responses in children born to mothers infected with hepatitis C virus.

Authors:  Samer S El-Kamary; Mohamed Hashem; Doaa A Saleh; Sayed F Abdelwahab; Maha Sobhy; Fatma M Shebl; Michelle D Shardell; G Thomas Strickland; Mohamed Tarek Shata
Journal:  J Pediatr       Date:  2012-08-09       Impact factor: 4.406

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.